Гепатопульмональный синдром

Обложка

Цитировать

Полный текст

Аннотация

Гепатопульмональный синдром (ГПС) является частым осложнением терминальных заболеваний печени. В основе ГПС лежит развитие дилатации легочных сосудов в ответ на повышение концентрации циркулирующих вазоактивных субстанций. Для постановки диагноза ГПС необходима триада признаков: заболевание печени и/или портальная гипертензия, дилатация легочных сосудов и гипоксемия. Основными лечебными мероприятиями при ГПС являются кислородотерапия и ортотопическая трансплантация печени.

Об авторах

Сергей Николаевич Авдеев

ФГБУ НИИ пульмонологии ФМБА России

Email: serg_avdeev@list.ru
д-р мед. наук, проф., рук. клин. отд. ФГБУ НИИ пульмонологии 105077, Россия, Москва, ул. 11-я Парковая, д. 32

Список литературы

  1. Krowka M.J. Hepatopulmonary syndromes. Gut 2000; 40: 1-4.
  2. Stoller J.K, Lange P.A, Westveer M.K et al. Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation - The Cleveland Clinic Experience. West J Med 1995; 163: 133-8.
  3. Hopkins W.E, Waggoner A.D, Barzilai B. Frequency and significance of intrapulmonary right - to - left shunting in end - stage hepatic disease. Am J Cardiol 1992; 70: 516-9.
  4. Swanson K.L, Weiner R.H, Krowka M.J. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41: 1122-9.
  5. Grace J.A, Angus P.W. Hepatopulmonary Syndrome: Update on Recent Advances in Pathophysiology, Investigation, and Treatment. J Gastroenterol Hepatol 2013; 28: 213-9.
  6. Nacif L.S, Andraus W, Pinheiro R.S et al. The hepatopulmonary syndrome. Arq Bras Cir Dig 2014; 27: 145-7.
  7. Fluckiger M. Vorkommen von trommelschlägelförmigen finger - endphalengen ohne chronische veränderungen an der lungen oder am herzen. Wien Med Wschr 1884; 34: 1457.
  8. Kennedy T.C, Knudson R.J. Exercise - aggravated hypoxemia and orthodexia in cirrhosis. Chest 1997; 72: 305-9.
  9. Abrams G.A, Jaffe C.C, Hoffer P.B et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 109: 1283-8.
  10. Seward J.B, Hayes D.L, Smith H.C et al. Platypnea - orthodeoxia: clinical profile, diagnostic work - up, management and report of 7 cases. Mayo Clin Proc 1984; 59: 221-31.
  11. Rolla G, Brussino L, Colagrande P et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997; 26: 842-7.
  12. Robin E.D, Laman D, Horn B.R et al. Platypnea related to orthodeoxia caused by true vascular lung shunts. N Engl J Med 1976; 294: 941-3.
  13. Alizadeh A.H.M, Fatemi S.R, Mirzaee V et al. Clinical features of hepatopulmonary syndrome in cirrhotic patients. World J Gastroenterol 2006; 12: 1954-6.
  14. Andrivet P, Cadranel J, Housset B et al. Mechanisms of impaired arterial oxygenation in patients with liver cirrhosis and severe respiratory insufficiency. Effects of indomethacin. Chest 1993; 103: 500-7.
  15. Lima B.L.G, Franca A.V.C, Pazin-Filho A et al. Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome. Mayo Clin Proc 2004; 79: 42-8.
  16. Rodriguez-Roisin R, Roca J, Agusti A.G et al. Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis 1987; 135: 1085-92.
  17. Schenk P, Schöniger-Hekele M, Fuhrmann V et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125: 1042-52.
  18. Krowka M.J, Dickson E.R, Cortese D.A. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993; 104: 515-21.
  19. Bruix J, Bosch J, Kravetz D et al. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88: 430-5.
  20. Krowka M.J, Cortese D.A. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology 1990; 11: 138-42.
  21. Pizcueta P, Pique J.M, Fernandez M et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-15.
  22. Cremona G, Higenbottam T.W, Mayoral V et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 1995; 8: 1883-5.
  23. Rolla G, Brussino L, Colagrande P et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997; 26: 842-7.
  24. Fallon M.B, Abrams G.A. Pulmonary dysfunction in chronic liver disease. Hepatology 2000; 32: 859-65.
  25. Nunes H, Lebrec D, Mazmanian M et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 2001; 164: 879-85.
  26. Brussino L, Bucca C, Morello M et al. Effect on dyspnoea and hypoxemia of inhaled NG-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003; 362: 43-4.
  27. Schenk P, Madl C, Rezaie-Majid S et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000; 133: 701-6.
  28. Zhang H.Y, Han D.W, Wang X.G et al. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol 2005; 11: 567-72.
  29. Rabiller A, Nunes H, Lebrec D et al. Prevention of gram - negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002; 166: 514-7.
  30. Henriksen J.H, Staun-Olsen P, Fahrenkrug P et al. Vasoactive intestinal polypeptide (VIP) in cirrhosis: arteriovenous extraction in different vascular beds. Scand J Gastroenterol 1980; 15: 787-92.
  31. Hortnagl H, Singer E.A, Lenz K et al. Substance-P is markedly increased in plasma of patients with hepatic coma. Lancet 1984; 1: 480-3.
  32. Gines P, Jimenez W, Arroyo V et al. Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology 1988; 8: 636-42.
  33. Gómez F.P, Barberà J.A, Roca J et al. Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology 2006; 43: 1084-91.
  34. Dinh-Xuan A.T, Naeije R. The hepatopulmonary syndrome: NO way out? Eur Respir J 2004; 23: 661-2.
  35. Davis H.H, 2nd, Schwartz D.J, Lefrak S.S et al. Alveolar - capillary oxygen disequilibrium in hepatic cirrhosis. Chest 1978; 73: 507-11.
  36. Edell E.S, Cortese D.A, Krowka M.J et al. Severe hypoxemia and liver disease. Am Rev Respir Dis 1989; 140: 1631-5.
  37. Rydell R, Hoffbauer F.W. Multiple pulmonary arteriovenous fistulas in juvenile cirrhosis. Am J Med 1956; 21: 450-60.
  38. Berthelot P, Walker J.G, Sherlock S et al. Arterial changes in the lungs in cirrhosis of the liver - lung spider nevi. N Engl J Med 1966; 274: 291-8.
  39. Robin E.D, Horn B, Goris M.L et al. Detection, quantitation and pathophysiology of lung spiders. Trans Assoc Am Physicians 1975; 88: 202-16.
  40. Genovesi M.G, Tierney D.F, Taplin G.V et al. An intravenous radio - nuclide method to evaluate hypoxemia caused by abnormal alveolar vessels. Limitation of conventional techniques. Am Rev Respir Dis 1976; 114: 59-65.
  41. Wolfe J.D, Tashkin D.P, Holly F.E et al. Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method. Am J Med 1977; 63: 746-54.
  42. Williams A, Trewby P, Williams R et al. Structural alterations to the pulmonary circulation in fulminant hepatic failure. Thorax 1979; 34: 447-53.
  43. Gotway M.B, Dotson R.H, Dawn S.K. Hypoxemia in a patient with end - stage liver disease. Clin Pulm Med 2005; 12: 61-6.
  44. Thorens J.B, Junod A.F. Hypoxemia and liver cirrhosis: a new argument in favour of a diffusion - perfusion defect. Eur Respir J 1992; 5: 754-6.
  45. Krowka M.J, Cortese D.A. Severe hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bimesylate. Mayo Clin Proc 1987; 62: 164-73.
  46. Schenk P, Fuhrmann V, Madl C et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002; 51: 853-9.
  47. Rodriguez-Roisin R, Krowka M.J et al. ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary - hepatic vascular disorders (PHD). Eur Respir J 2004; 24: 861-80.
  48. Offer J, Green L, Houghton A.R, Campbell J. A case of hepatopulmonary syndrome. Echo Res Pract 2015; 2: K25-7.
  49. Kamath P.S. Portopulmonary hypertension and hepatopulmonary syndrome. J Gastroenterol Hepatol 2002; 17: S253-5.
  50. Shub C, Tajik A.J, Seward J.B et al. Detecting intrapulmonary right - to - left shunt with contrast echocardiography: observations in a patient with diffuse pulmonary arteriovenous fistulas. Mayo Clin Proc 1976; 51: 81-4.
  51. Karabulut A, Iltumur K, Yalcin K et al. Hepatopulmonary syndrome and right ventricular diastolic functions: an echocardiographic examination. Echocardiography 2006; 23: 271-8.
  52. Zamirian M, Aslani A, Shahrzad S. Left atrial volume: A novel predictor of hepatopulmonary syndrome. Am J Gastroenterol 2007; 102: 1392-6.
  53. Wang Y.W, Lin H.C. Recent advances in hepatopulmonary syndrome. J Chin Med Assoc 2005; 68: 500-5.
  54. Abrams G.A, Nanda N.C, Dubovsky E.V et al. The use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998; 114: 305-10.
  55. Ferreira M.A.P, Barreto S.S.M, Knorst M.M et al. Semiquantitative echocardiographic evaluation of intrapulmonary vascular dilatations: correlation with evaluation of shunt levels and pulmonary function parameters. J Bras Pneumol 2009; 35: 106-13.
  56. Scott V.L, Dodson S.F, Kang Y. The hepatopulmonary syndrome. Surg Clin North Am 1999; 79: 23-41.
  57. Ryu J.K, Oh J.H. Hepatopulmonary syndrome: angiography and therapeutic embolization. Clin Imaging 2003; 27: 97-100.
  58. Castro M, Krowka M.J. Hepatopulmonary syndrome: a pulmonary vascular complication of liver disease. Clin Chest Med 1996; 17: 35-48.
  59. Saad N.E.A, Lee D.E, Waldman D.L et al. Pulmonary arterial coil embolization for the management of persistent Type 1 hepatopulmonary syndrome after liver transplantation. J Vasc Interv Radiol 2007; 18: 1576-80.
  60. Mc-Adams H.P, Erasmus J, Crockett R, et al. The hepatopulmonary syndrome: radiologic findings in 10 patients. AJR Am J Roentgenol 1996; 166: 1379-85.
  61. Lee K.N, Lee H.J, Shin W.W et al. Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature. Radiology 1999; 211: 549-53.
  62. Soderman C, Juhlin-Dannfelt A, Lagerstrand L et al. Ventilation - perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J Hepatol 1994; 21: 52-7.
  63. Cadranel J, Milleron B, Cadranel J.F et al. Severe hypoxemia associated intrapulmonary shunt in a patient with chronic liver disease: improvement after medical treatment. Am Rev Respir Dis 1992; 146: 526-7.
  64. Milhe F, Reynaud-Gaubert M, Magnan A et al. Oxygenation improvement with almitrine bismesylate in the hepatopulmonary syndrome. Respiratory Medicine Extra 2006; 2: 81-4.
  65. Krowka M.J, Cortese D.A. Severe hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bimesylate. Mayo Clin Proc 1987; 62: 164-73.
  66. Nakos G, Evrenoglou D, Vassilakis N et al. Haemodynamics and gas exchange in liver cirrhosis: the effect of orally administered almitrine bimesylate. Respir Med 1993; 87: 93-8.
  67. Rabiller A, Nunes H, Lebrec D et al. Prevention of gram - negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002; 166: 514-7.
  68. Zhang J, Ling Y, Tang L et al. Pentoxifylline attenuation of experimental hepatopulmonary syndrome. J Appl Physiol 2007; 102: 949-55.
  69. National Institutes of Health Pilot study of pentoxifylline for hepatopulmonary syndrome [online]: identifier: NCT00593658. 2008. http://clinicaltrials.gov/ct2/show/NCT00593658?term=NCT00593658&rank=1
  70. Krug S, Seyfarth H.J, Hagendorff A et al. Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. Eur J Gastroenterol Hepatol 2007; 19: 1140-3.
  71. Allgaier H.P, Haag K, Ochs A et al. Hepatopulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stentshunt (TIPS). J Hepatol 1995; 23: 102-5.
  72. Riegler J.L, Lang K.A, Johnson S.P et al. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995; 109: 978-83.
  73. Selim K.M, Akriviadis E.A, Zuckerman E et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. J Am Coll Gastroenterol 1998; 93: 455-8.
  74. Martinez-Palli G, Drake B.B, Garcia-Pagan J.C et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11: 6858-62.
  75. Yamada R, Sato M, Kawabata M et al. Segmental obstruction of the hepatic inferior vena cava treated with transluminal angioplasty. Radiology 1983; 149: 91-6.
  76. De B.K, Sen S, Biswas P.K et al. Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology 2002; 122: 897-903.
  77. White R.E, Lynch-Nyhan A, Terry P et al. Pulmonary arteriovenous malformations: techniques and long - term outcome of embolotherapy. Radiology 1988; 169: 663-9.
  78. Poterucha J.J, Krowka M.J, Dickson E.R, et al. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 1995; 21: 96-100.
  79. Fukushima K.Y, Yatsuhashi H, Kinoshita A et аl. Two cases of hepatopulmonary syndrome with improved liver function following long - term oxygen therapy. J Gastroenterol 2007; 42: 176-80.
  80. Krowka M.J, Mandell M.S, Ramsay M.A et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174-82.
  81. Hoeper M.M, Krowka M.J, Strassburg C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-8.
  82. Lange P.A, Stoller J.K. Hepatopulmonary syndrome: effects of liver transplantation. Clin Chest Med 1996; 17: 115-23.
  83. Arguedas M, Abrams G.A, Krowka M.J et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37: 192-7.

© ООО "Консилиум Медикум", 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах